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There are many different biochemical processes responsible for the hepatocelluar carcinoma (HCC)
development that can be targeted for the prevention or halt progression of the HCC. Non-selective betablockers (NSBB) affects a multitude of intracellular biochemical and signaling pathways involved in
carcinogenesis. Aim: To determine if NSBB may be protective for HCC in patients with cirrhosis and
portal hypertension. Methods: We retrospectively enrolled 200 patients from medical records diagnosed
with cirrhosis and portal hypertension between January 2001 and December 2013. Eighteen patients were
excluded (taking selective beta-blocker and/or unavailable medical records). The etiology of cirrhosis, use
of NSBB, demographics and the presence of HCC was collected. Result: There were 140 males and 42
females. The mean age for portal hypertension with cirrhosis without HCC was 53.5 ± 11.4 & with HCC
was 62.2 ± 9.5 years. Univariate analysis of the association of NSBB with HCC yielded OR = 0. 11 (95% CI:
0.04 to 0.25); p < 0.0001, suggesting a protective effect of NSBB. Multivariable analysis suggests virtually
no change when the Odds ratio (OR) was adjusted for diabetes mellitus (DM), alcohol use, Hepatitis B virus
(HBV) status, Black race and age ≥ 53. There was a slight increase in the OR adjusted for statin use.
Conclusion: This study highlights association of NSBB use in the patients with liver cirrhosis and portal
hypertension for prevention of HCC.
[N A J Med Sci. 2015;8(3):105-108. DOI: 10.7156/najms.2015.0803105]
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in men and seventh most common cancer in women. 1
According to American Cancer Society, about 30,000 new
cases are diagnosed each year. Major risk factors for
development of HCC include hepatitis C virus infection
(HCV), hepatitis B virus infection (HBV), alcoholic liver
disease and nonalcoholic fatty liver disease (NAFLD), but
virtually cirrhosis of almost any cause is the risk factor. Ageadjusted incidence of the HCC has been going up in recent
decades. The incidence has almost doubled in the past two
decades and it is expected to continue to rise as a
consequence of high hepatitis C infection rates between 1960
and 1990.2
There are many biochemical processes responsible for the
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HCC development that can be targeted for the prevention or
halt progression of the HCC. Various biochemical processes
include (1) increased level of reactive oxygen species (ROS)
mediated lipid peroxides, which participate in chain reactions
that amplify damage to bio molecules, including DNA and at
the end result of DNA attack gives rise to the mutations that
may involve tumor suppressor genes or oncogenes, and cause
cancer.3 (2) Mitochondria are crucial for cellular energy
production, cell survival and major regulator in the intrinsic
apoptotic pathway so mitochondrial dysfunction by certain
gene mutations in mitochondria may lead to cause apoptotic
resistance, evolves into hepatocarcinogenesis and promote
HCC progression.4 (3) HCV proteins trigger ROS generation
through induction of NADPH oxidase 4 expressions and
autocrine TGFβ-dependent mechanism. The ROS then
activates mitogen-activated proteins, extracellular signal–
regulated kinases, or angiogenesis along with induction of
DNA damage.5 (4) Vascular endothelial growth factor
(VEGF) is associated with the development of liver tumor
neovascularization and basic fibroblast growth factor (FGF)
is involved in infiltration of cancer cells into the tumor
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capsule in HCC.6 (5) Linear relation exists between level of
catecholamines and severity of liver disease. More advanced
disease is associated with higher levels of catecholamines.7
(6) Bacterial translocation, across the edematous bowel wall,
represents a large inflammatory load to the cirrhotic liver. It
exposes hepatocytes to chronic inflammation, thus
contributing to carcinogenesis.8
Non-selective beta-blockers (NSBB) affects a multitude of
above mentioned intracellular biochemical and signaling
pathways involved in carcinogenesis. These include (1)
preventing lipid peroxidation of the membranes, (2)
attenuating mitochondrial dysfunction, (3) inhibiting Baxmediated cytochrome C release, NADPH oxidase and protein
kinase C activity, (4) decreasing vascular endothelial growth
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factor (VEGF) / basic fibroblast growth factor gene
expression. (5) antagonizing catecholamine driven cell
migration, tumor angiogenesis, invasiveness and proliferation
(6) decreasing bacterial translocation and reducing the partial
load of pro inflammatory bacterial products. (7) preventing
or reducing cancer progression, by inhibiting cAMPresponsive element-binding protein (CREB), NF-κB, and
activator protein (AP-1), inducting apoptosis, or reducing
matrix metalloproteinase (MMP)-9 activation and tumor
angiogenesis.9-16
Because NSBB are regularly used as prophylaxis for portal
hypertension in cirrhotic liver disease, the purpose of this
study was to look for a possible association of NSBB with
HCC.

Figure 1. Flow chart of the protocol.

METHODS
Protocol, patients and setting
This is a retrospective analysis of 200 consecutive patients,
age ≥ 18 years, from Jan 2001 to 31 Dec 2013, with a
diagnosis of portal hypertension and cirrhosis, with or
without HCC.
The institution at which the study was
conducted is a 700-bed tertiary-care teaching hospital in
northeastern USA. Excluded from the original cohort were
16 patients taking a selective β blocker and 2 patients for
whom insufficient data were available. The flow chart of the
study is shown in Figure 1.
The study was given exempt status by the Institutional
Review Board of St. Joseph’s Healthcare System, which
operates the center where the study was conducted.

Statistical analyses
For this study, α was set at 0.05; thus values of p < 0.05 were
required for statistical significance. Potential confounders
were considered as covariates if baseline differences between
the groups had a p-value ≤ 5α, i.e., p ≤ 0.25. The continuous
variable (age) was found to be not significantly different
from a normal distribution by the D’agostino-Pearson
omnibus normality test. Therefore age is expressed as mean
±1. Standard deviation (SD) and between-group age
differences evaluated by the t-test.
The cutoff for
dichotomizing age for the two groups was determined by
receiver operating characteristic (ROC) curve analysis.
For categorical variables, univariate association was
evaluated by cross-tabulating exposures with the outcome
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and tested for statistical significance with Fisher’s exact test
for 2 x 2 contingency tables and with chi-square for tables
with larger numbers of cells (race/ethnicity). Because of the
retrospective nature of the study, the odds ratio (OR) and
95% confidence interval (95% CI) was used as a measure of
effect size. Multivariable association, using covariates as
described, above, was assessed by binary logistic regression.
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0.1, CI: 0.04 to 0.24) and diabetes mellitus (OR: 0.1, CI: 0.04
to 0.25) were included as covariates. Interestingly, statins
slightly mitigated the protective effect of NSBB, the OR,
adjusted for statins, was 0.12 (95% CI: 0.05 to 0.29). (Figure
2)

Analyses were conducted using the Prism® software
(GraphPad Corp., San Diego, CA, USA) and SPSS® v. 21
(IBM Corp., Armonk, NY, USA).
Table 1. Baseline Demographics.
Characteristics
Age (Mean±SD)
Gender (F/M)
Race/Ethnicity
Black vs all others
Hispanic vs all others
White vs all others
Others vs all others
DM (+/-)
HCV (+/-)
HBV (+/-)
Ethanol use (+/-)
Statin use (+/-)

HCC Present (42)
62.2 ±9.5
7/35

HCC Absent (140)
53.5 ±11.4
35/105

12
19
8
3
9/33
21/21
8/34
16/26
5/37

21
77
33
9
47/93
57/83
13/127
77/63
4/136

p- value
< 0.0001
0.303
0.242
0.066
0.291
0.675
0.182
0.283
0.099
0.078
0.032

RESULTS
Baseline Characteristics of the Subjects
Table 1 gives the demographic and clinical characteristics of
the two groups. There were 140 males and 42 females. The
mean age for portal hypertension with cirrhosis without HCC
was 53.5 ± 11.4 & HCC was 62.2 ± 9.5 years. The
distribution of race was 96 (52.7%) Hispanic & 41 (22.5%)
Caucasian. Causes of cirrhosis were alcohol 93 (51%),
followed by HCV 78 (42.8%). Ninety-nine (Propranolol = 97,
Nadolol = 2) patients were on NSBB. Forty-two patients (M
= 35, F = 7) had a diagnosis of HCC. Among those
examined, age, race/ethnicity, diabetes, presence of HBV,
ethanol and statin use demonstrated p-values ≤ 0.25 and were
included in the multivariable model. Race/ethnicity data were
further dichotomized post hoc. This analysis yielded black
race (p = 0.066) as a covariate.
Association of NSBB with HCC
Analysis of the association of NSBB with HCC on a
univariate base yielded OR = 0. 11 (95% CI: 0.04 to 0.25); p
< 0.0001, suggesting a protective effect of NSBB. In males,
the odds were lower in NSBB [OR 0.112, CI 95% (0.042,
0.295) p < 0.0001]. Significantly lower odds were also found
in HCV [OR 0.17, CI 95% (0.056, 0.513) p < 0.0001],
alcohol [OR 0.039, CI 95% (0.005, 0.309) p < 0.0001],
Hispanic [OR 0.146, CI 95% (0.044, 0.479) p = 0. 0008] and
black race [OR 0.062, CI 95% (0.01, 0.386) p = 0. 001].
Statistical significance was not reached in females [OR 0.174,
p= 0.051], HBV subgroup [p = 1] and Caucasian subgroup [p
= 0. 2]. Multivariable analysis suggests virtually no change in
the OR and 95% CI when age [at a cutoff of 53 years] (OR:
0.11, CI: 0.04 to 0.28), black race (OR: 0.1, CI: 0.04 to 0.24),
HBV status (OR: 0.11, CI: 0.04 to 0.26), ethanol use (OR:

Figure 2. Forest plot comparing univariate OR and 95% confidence interval
(CI) with those adjusted for covariates.

DISCUSSION
In our study, we assessed the association of NSBB in the
HCC prevention in patients with cirrhosis and portal
hypertension. We found that NSBB treatment is associated
with lower incidence of the HCC in patients with cirrhosis
and portal HTN.
As the incidence of HCC is increasing, it is important for us
to look for preventive measures to stop the growing burden
and health care cost of HCC.2 Use of HBV vaccination
dramatically reduced the prevalence of HBV infection and
there has been a concomitant decrease in the incidence of
hepatocellular carcinoma.17 The literature suggests the use of
antiviral therapy to control HBV and HCV infection and
achieving sustained viral response substantially reduces but
does not eliminate the risk of HCC.18-20 Statin use also has
been associated with a lower risk of HCC in patients with
HBV and HCV infection.21-22 One common limitation exists
with all above-mentioned preventive interventions; that is,
once cirrhosis is established the effectiveness of these
interventions to prevent HCC development and progression
is questionable.18,20-23 While, NSBB is the only intervention
which might work in the patients with advanced cirrhosis to
prevent HCC.5
To our knowledge, two retrospective studies have been done
so far to evaluate the protective effect of NSBB in the
patients with cirrhosis. Nkontchou et al retrospectively
reviewed 291 patients with compensated hepatitis C virus
related cirrhosis showed NSBB use decreased HCC
incidence.5 Kim et al reviewed 273 patients with all cause
cirrhosis and it did not show any relation between NSBB and
HCC incidence.24 There are many other benefits of NSBB
reported in the literature for cirrhotic patients and some
tumors. NSBB has been shown to decrease mortality in
patients with cirrhosis via reducing the rate of gastrointestinal
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bleeding and decreasing incidence of spontaneous bacterial
peritonitis.25,26 In ovarian and breast cancer NSBB has shown
promising results in tumor prevention and growth. 27,28 The
anti-angiogenic effects of NSBB in hemangiomas are well
documented.29
It is clear from our study that individuals who were not on
the NSBB were more likely to develop HCC. NSBB is easily
available, affordable and are also well tolerated by most of
the patients. So this strategy may decrease incidence of HCC
in patients with cirrhosis.

9.

10.

11.

12.

13.

Major limitation of our study are unknown compliance and
duration of NSBB therapy, duration from onset of portal
HTN to development of HCC, and data regarding antiviral
therapy. Short follow up period which is 3 years.

14.

15.

CONCLUSION
This study highlights association of NSBB use in patients
with liver cirrhosis and portal hypertension for prevention of
HCC. It is also clear that further studies, especially
randomized control trial need to be carried out to evaluate the
importance of NSBB in HCC prevention. If favorable effects
of NSBB will be confirmed in such a trial, this would be
significant since the majority of cirrhotic patients would need
beta blockers and they are at the high risk for HCC.
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